Director Gary S. Stetz II of Hepion Pharmaceuticals, Inc. filed a statement of changes in beneficial ownership on October 27, 2026, reporting the acquisition of stock options granted on October 23, 2026.

Key Highlights

  • Reporting person: Gary S. Stetz II, a director of Hepion Pharmaceuticals, Inc.
  • Options acquired: 510,000 stock options acquired on October 23, 2026, with an exercise price of $0.14 per share.
  • Vesting schedule: 42,500 options vest in equal amounts monthly over 12 months from the date of grant, according to the filing.
  • Expiration date: The options expire on October 23, 2036, and the underlying security is common stock.
  • Price of derivative security: The filing lists the price of the derivative security as $0.
  • Post-transaction holdings: Following the reported transaction, Stetz beneficially owns 809,000 derivative securities directly.

Stetz Option Grant Details at Hepion Pharmaceuticals

According to the filing, Gary S. Stetz II, serving as a director of Hepion Pharmaceuticals, Inc. (OTC:HEPA), acquired 510,000 stock options on October 23, 2026. The options carry an exercise price of $0.14 and are exercisable into an equivalent number of shares of common stock. The filing designates the transaction code as "A," indicating an acquisition, and records the price of the derivative security as $0. Ownership is reported as direct.

The filing notes in its explanation of responses that 42,500 options vest in equal amounts monthly over 12 months from the date of grant. Following this transaction, Stetz's total directly held derivative securities amount to 809,000, as reported in Table II of the disclosure. Hepion Pharmaceuticals is a biopharmaceutical company focused on drug development, and Stetz's address on file is c/o Hepion Pharmaceuticals, Inc., 22 West St., Suite 1B, Red Bank, New Jersey 07701.

The filing was signed by Gary S. Stetz II on October 27, 2026, and was submitted as a filing by one reporting person. No amendment date is listed, indicating this is an original filing. No transactions were reported in Table I covering non-derivative securities.

What Was Disclosed

The filing reports the October 23, 2026, grant of 510,000 stock options at an exercise price of $0.14 to director Gary S. Stetz II of Hepion Pharmaceuticals, Inc., with 42,500 options vesting monthly over 12 months and an expiration date of October 23, 2036.